NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) – MiNK Therapeutics, Inc. (“MiNK”), a clinical-stage biotechnology company pioneering the discovery, development and commercialization of allogeneic, ready-to-use natural killers employment and invariant T-cell therapies (iNKT) to treat cancer and other immune-mediated diseases, today announced the price of its initial public offering of 3,333,334 common shares at the public offering price of 12.00 $ per share. The gross proceeds of the Offering, before deducting subscription rebates and commissions and other offering fees payable by MiNK, are expected to be approximately $ 40 million. The shares are expected to begin trading on the Nasdaq Global Market on October 15, 2021 under the symbol “INKT”. The offer is expected to close on or around October 19, 2021, subject to the satisfaction of customary closing conditions. In addition, MiNK has granted the underwriters a 30-day option to purchase up to 500,000 additional common shares at the initial public offering price, less underwriting discounts and commissions. All shares are offered by MiNK.
Evercore ISI and William Blair are acting as book co-managers for the offering. B. Riley and Baird act as co-managers of the offer.
A registration statement relating to the offering of these securities has been filed with the United States Securities and Exchange Commission and became effective October 14, 2021. The offering is being made only by way of a prospectus, copies of which can be obtained from Evercore Group LLC, Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, or by phone at (888) 474-0200, or by e-mail at [email protected] and William Blair & Company, LLC, Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, or by phone at (800) 621-0687, or by email at prospectus @ williamblair.com. Copies of the final prospectus, when available, relating to the offering will be available at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy such securities, and there will be no sale of such securities in any state or jurisdiction in which such an offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic invariant natural killer T cell therapies (iNKTs) to treat cancer and other immune-mediated diseases. MiNK advances a pipeline of native and next-generation iNKT programs, with a platform designed to facilitate scalable and repeatable manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY.
This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on such forward-looking statements, including statements regarding the completion, timing and size of the initial public offering and the commencement of trading on the Nasdaq Global Market. Each forward-looking statement is subject to the uncertainties inherent in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed under the conditions described or not at all. The completion of the Initial Public Offering and the terms thereof are subject to many factors, many of which are beyond MiNK’s control, including, without limitation, market conditions, failed trading conditions customary closing and other factors discussed in the “Risk Factors” section of the preliminary prospectus which is part of the actual registration statement filed with the SEC. All forward-looking statements contained in this press release are based on the current expectations of the management team of MiNK and speak only as of the date hereof and MiNK specifically disclaims any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law.
MiNK Therapeutics Kimberly Ha KKH Advisors 917-291-5744 [email protected]
Copyright 2021 GlobeNewswire, Inc.